New Vice President for LEO Pharma UK and Ireland

LEO Pharma, a leader in medical dermatology, has appointed Sarah Kleinpeter as Vice President of UK and Ireland. Sarah joins the company from GlaxoSmithKline where she was previously General Manager for Finland operations.

Sarah has over 14 years of pharmaceutical experience, having held local and global leadership positions in both R&D and commercial teams. She has a strong record of launching specialty pharmaceuticals across the G7, including several biologic treatments.

Sarah started her career in GSK R&D, supporting the development of new medicines across Rare Diseases, Ophthalmology, Cardiovascular, Respiratory and Immuno-Inflammation. She later moved to the Global and US Commercial businesses, directing global launches in Specialty Products. Following several commercial roles, Sarah was appointed as General Manager of GSK in Finland, leading a portfolio including Respiratory, HIV, Vaccines, Classic and Established Products, as well as building a new Oncology division.

Sarah succeeds the outgoing Vice President and Managing Director Geraldine Murphy, who was in charge of UK and Ireland operations for over 8 years.

Discussing her new role at the company, Sarah commented, “I am excited to join LEO Pharma, and share many of the same values as the business, most notably, putting patients first. The opportunity to address the unmet needs of dermatology patients is something we can achieve through our strong pipeline, matched with our company culture and people.”

“My priorities will be understanding patient and external stakeholder needs and challenges to inform our thinking, and to strengthen our ability to be pioneers in the dermatology space. I am a firm believer in being externally focused, whilst also fostering a strong internal culture where employees can flourish. We have the potential and ambition to be the preferred dermatology care partner, improving people’s lives around the world, and I believe we have an exciting future ahead.”

Media contact information:

Jonathan Fox, Senior External Affairs & Corporate Communications Manager, LEO Pharma:

LEO Pharma Communications Inbox:

About LEO Pharma

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

UK/IE/MAT-42989    February 2021